Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Nadolol matches propranolol efficacy in angina; extends once-daily beta-blocker options but leaves optimal dosing open in larger cohorts.
The effect of nadolol, a new long-acting beta-adrenergic blocking drug, on exercise tolerance was compared with propranolol in a randomised, double-blind crossover study involving 14 patients with angina pectoris caused by coronary artery disease. Exercise tolerance was evaluated by graded upright exercise testing to symptom-tolerated maximal exercise. Cardiac function was evaluated by sequential phonocardiograms, echocardiograms, and chest x-rays synchronised to end-diastole.
No takes yet. Share an insight, caveat, or question.
Turner et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: